Meeting
2022 ASCO Genitourinary Cancers Symposium
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Authors
Sean Matthew McBride
Memorial Sloan Kettering Cancer Center, New York, NY
Sean Matthew McBride , Tamim Niazi , Scott Williams , Ian D. Davis , Martin R. Stockler , Andrew James Martin , Karen Bracken , Felicia T. Roncolato , Lisa Horvath , Shomik Sengupta , Jarad Martin , Tee Lim , Simon Hughes , Raymond S. McDermott , James W.F. Catto , Paul J. Kelly , Wendy R. Parulekar , Scott Carlyle Morgan , Ricardo A. Rendon , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04136353
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS284)
DOI
10.1200/JCO.2022.40.6_suppl.TPS284
Abstract #
TPS284
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Gastrointestinal organoid cultures for functional evaluation of oncogenic loci.
First Author: Ameen Abdulla Salahudeen
Poster
2019 ASCO Annual Meeting
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
First Author: Tian Zhang
Poster
2015 ASCO Annual Meeting
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).
First Author: Scott G. Williams
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang